1887

Abstract

Hepatitis C virus (HCV) infections are a major public-health concern. New antiviral drugs are needed urgently to complement and improve the efficacy of current chemotherapies. The morphogenesis of HCV represents an interesting, and still unexploited, novel molecular target. -Glucosidase inhibitors derived from the glucose analogue deoxynojirimycin (DNJ) inhibit viral morphogenesis via perturbation of the -glycosylation pathway and hence the misfolding of viral glycoproteins that depend on certain -glycans for correct folding. Due to the heavy -glycosylation of HCV glycoproteins, it was hypothesized that such inhibitors would also affect HCV morphogenesis. To study the effect of -glucosidase inhibitors on viral morphogenesis and binding properties, HCV virus-like particles (VLPs) were produced by using baculovirus loaded with HCV structural-protein genes. Here, it is demonstrated that, in the presence of these -glucosidase inhibitors, viral glycoproteins synthesized and retained in the endoplasmic reticulum (i) contain unprocessed, triglucosylated -glycans, (ii) are impaired in their interaction with calnexin and (iii) are at least partially misfolded. Moreover, it is shown that, although the production of VLPs is not affected by -glucosidase inhibitors, these VLPs contain unprocessed, triglucosylated -glycans and potentially misfolded glycoproteins. Finally, it is demonstrated that VLPs produced in the presence of -glucosidase inhibitors have impaired binding properties to hepatoma cells. The inhibitors of morphogenesis studied here target steps of the HCV viral cycle that may prevent or delay viral resistance. These -glucosidase inhibitors may prove to be useful molecules to fight HCV infection in combination protocols.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81503-0
2006-04-01
2019-11-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/87/4/861.html?itemId=/content/journal/jgv/10.1099/vir.0.81503-0&mimeType=html&fmt=ahah

References

  1. Bartenschlager, R., Frese, M. & Pietschmann, T. ( 2004; ). Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 63, 71–180.
    [Google Scholar]
  2. Baumert, T. F., Ito, S., Wong, D. T. & Liang, T. J. ( 1998; ). Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 72, 3827–3836.
    [Google Scholar]
  3. Blissard, G. W. ( 1996; ). Baculovirus–insect cell interactions. Cytotechnology 20, 73–93.[CrossRef]
    [Google Scholar]
  4. Braakman, I. & van Anken, E. ( 2000; ). Folding of viral envelope glycoproteins in the endoplasmic reticulum. Traffic 1, 533–539.[CrossRef]
    [Google Scholar]
  5. Branza-Nichita, N., Durantel, D., Carrouée-Durantel, S., Dwek, R. A. & Zitzmann, N. ( 2001; ). Antiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1-E2 heterodimers. J Virol 75, 3527–3536.[CrossRef]
    [Google Scholar]
  6. Branza-Nichita, N., Lazar, C., Durantel, D., Dwek, R. A. & Zitzmann, N. ( 2002; ). Role of disulfide bond formation in the folding and assembly of the envelope glycoproteins of a pestivirus. Biochem Biophys Res Commun 296, 470–476.[CrossRef]
    [Google Scholar]
  7. Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W. & Houghton, M. ( 1989; ). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359–362.[CrossRef]
    [Google Scholar]
  8. Choo, Q.-L., Richman, K. H., Han, J. H. & 11 other authors ( 1991; ). Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 88, 2451–2455.[CrossRef]
    [Google Scholar]
  9. Cocquerel, L., Meunier, J.-C., Pillez, A., Wychowski, C. & Dubuisson, J. ( 1998; ). A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol 72, 2183–2191.
    [Google Scholar]
  10. Cocquerel, L., Meunier, J.-C., Op de Beeck, A., Bonte, D., Wychowski, C. & Dubuisson, J. ( 2001; ). Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2. J Gen Virol 82, 1629–1635.
    [Google Scholar]
  11. Davis, G. L., Albright, J. E., Cook, S. F. & Rosenberg, D. M. ( 2003; ). Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 9, 331–338.[CrossRef]
    [Google Scholar]
  12. Dubuisson, J. ( 2000; ). Folding, assembly and subcellular localization of hepatitis C virus glycoproteins. Curr Top Microbiol Immunol 242, 135–148.
    [Google Scholar]
  13. Dubuisson, J., Hsu, H. H., Cheung, R. C., Greenberg, H. B., Russell, D. G. & Rice, C. M. ( 1994; ). Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol 68, 6147–6160.
    [Google Scholar]
  14. Durantel, D., Branza-Nichita, N., Carrouée-Durantel, S., Butters, T. D., Dwek, R. A. & Zitzmann, N. ( 2001; ). Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J Virol 75, 8987–8998.[CrossRef]
    [Google Scholar]
  15. Durantel, D., Carrouée-Durantel, S., Branza-Nichita, N., Dwek, R. A. & Zitzmann, N. ( 2004; ). Effects of interferon, ribavirin, and iminosugar derivatives on cells persistently infected with noncytopathic bovine viral diarrhea virus. Antimicrob Agents Chemother 48, 497–504.[CrossRef]
    [Google Scholar]
  16. Dwek, R. A., Butters, T. D., Platt, F. M. & Zitzmann, N. ( 2002; ). Targeting glycosylation as a therapeutic approach. Nat Rev Drug Discov 1, 65–75.[CrossRef]
    [Google Scholar]
  17. Foster, G. R. ( 2004; ). Past, present, and future hepatitis C treatments. Semin Liver Dis 24 (Suppl. 2), 97–104.[CrossRef]
    [Google Scholar]
  18. Fried, M. W., Shiffman, M. L., Reddy, K. R. & 11 other authors ( 2002; ). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347, 975–982.[CrossRef]
    [Google Scholar]
  19. Fung, S. K. & Lok, A. S. ( 2004; ). Management of hepatitis B patients with antiviral resistance. Antivir Ther 9, 1013–1026.
    [Google Scholar]
  20. Helenius, A. & Aebi, M. ( 2004; ). Roles of N-linked glycans in the endoplasmic reticulum. Annu Rev Biochem 73, 1019–1049.[CrossRef]
    [Google Scholar]
  21. Johnson, V. A., Brun-Vézinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., Pillay, D., Schapiro, J., Telenti, A. & Richman, D. ( 2005; ). Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 13, 51–57.
    [Google Scholar]
  22. King, L. A. & Possee, R. D. ( 1992; ). The Baculovirus Expression System: a Laboratory Guide, p. 229. London: Chapman & Hall.
  23. Liang, T. J. & Heller, T. ( 2004; ). Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 127, S62–S71.[CrossRef]
    [Google Scholar]
  24. Lindenbach, B. D., Evans, M. J., Syder, A. J. & 8 other authors ( 2005; ). Complete replication of hepatitis C virus in cell culture. Science 309, 623–626.[CrossRef]
    [Google Scholar]
  25. Locarnini, S., Hatzakis, A., Heathcote, J., Keeffe, E. B., Liang, T. J., Mutimer, D., Pawlotsky, J.-M. & Zoulim, F. ( 2004; ). Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9, 679–693.
    [Google Scholar]
  26. Manns, M. P., McHutchison, J. G., Gordon, S. C. & 7 other authors ( 2001; ). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958–965.[CrossRef]
    [Google Scholar]
  27. Pawlotsky, J.-M. ( 2005; ). Current and future concepts in hepatitis C therapy. Semin Liver Dis 25, 72–83.[CrossRef]
    [Google Scholar]
  28. Poynard, T., Ratziu, V., Benhamou, Y., Opolon, P., Cacoub, P. & Bedossa, P. ( 2000; ). Natural history of HCV infection. Baillières Best Pract Res Clin Gastroenterol 14, 211–228.[CrossRef]
    [Google Scholar]
  29. Saunier, B., Triyatni, M., Ulianich, L., Maruvada, P., Yen, P. & Kohn, L. D. ( 2003; ). Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J Virol 77, 546–559.[CrossRef]
    [Google Scholar]
  30. Seeff, L. B. ( 2002; ). Natural history of chronic hepatitis C. Hepatology 36, S35–S46.[CrossRef]
    [Google Scholar]
  31. Tellinghuisen, T. L. & Rice, C. M. ( 2002; ). Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol 5, 419–427.[CrossRef]
    [Google Scholar]
  32. Triyatni, M., Saunier, B., Maruvada, P., Davis, A. R., Ulianich, L., Heller, T., Patel, A., Kohn, L. D. & Liang, T. J. ( 2002; ). Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol 76, 9335–9344.[CrossRef]
    [Google Scholar]
  33. Wakita, T., Pietschmann, T., Kato, T. & 9 other authors ( 2005; ). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11, 791–796.[CrossRef]
    [Google Scholar]
  34. Zhong, J., Gastaminza, P., Cheng, G. & 7 other authors ( 2005; ). Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102, 9294–9299.[CrossRef]
    [Google Scholar]
  35. Zitzmann, N., Mehta, A. S., Carrouée, S., Butters, T. D., Platt, F. M., McCauley, J., Blumberg, B. S., Dwek, R. A. & Block, T. M. ( 1999; ). Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc Natl Acad Sci U S A 96, 11878–11882.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.81503-0
Loading
/content/journal/jgv/10.1099/vir.0.81503-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error